350 rub
Journal Technologies of Living Systems №2 for 2013 г.
Article in number:
Clinical prospects of the key NF-B system components study in the tumors of breast cancer patients
Keywords: nuclear transcription factor NF-kappa B NF-&#61547 Bp65 NF-&#61547 Bp50 I&#61547 B&#61537 protein kinase Akt1 steroid hormone receptors HER2/neu breast cancer hormone sensitivity resistance
Authors:
A.M. Sherbakov, E.S. Gershtein, N.E. Kushlinskii
Abstract:
Contemporary knowledge about the molecular mechanisms of breast cancer development and progression and its sensitivity or resistance to various drugs allows to proceed from standardized averaged therapy regimens to so called "personalized medicine", i.e. to the prescription of treatment according to the individual patient-s features and biological characteristics of the tumor. This paper contains original data and a review of up to date publications on the role of nuclear transcription factor NF-B and related signaling proteins in the generation of breast cancer hormone and drug resistance, and the prospects of their clinical application.
Pages: 66-72
References
  1. Герштейн Е.С., Кушлинский Н.Е. Некоторые компоненты NF-kB сигнального пути в опухолях больных раком молочной железы: роль в прогнозе гормональной и лекарственной резистентности // Молекулярная медицина. 2011. № 4. С. 12 - 19.
  2. Герштейн Е.С., Кушлинский Н.Е., Давыдов М.И. Рецепторы семейства c-erbB как мишени молекулярно-направленной противоопухолевой терапии: достижения, проблемы, перспективы // Молекулярная медицина. 2010. № 4. С. 5 - 10.
  3. Герштейн Е.С., Кушлинский Н.Е., Щербаков А.М. и др. Сравнительный иммуноферментный анализ экспрессии и активности ядерного транскрипционного фактора NF-kB, его ингибитора IkBa и вышележащей эффекторной протеинкиназы Akt1 в опухолях больных раком молочной железы // Вопросы биологической, медицинской и фармацевтической химии. 2011. № 8. С. 56 ? 60.
  4. Герштейн Е.С., Овчинникова Л.К., Кушлинский Н.Е. Роль ядерного транскрипционного фактора NF-kappa B в этиологии, патогенезе и клиническом течении рака молочной железы // Вопросы биологической, медицинской и фармацевтической химии. 2009. № 5. С. 10 - 13.
  5. Герштейн Е.С., Щербаков А.М., Платова А.М. и др. Экспрессия и ДНК-связывающая активность ядерного транскрипционного фактора NF-kB в опухолях больных раком молочной железы // Бюллетень экспериментальной биологии и медицины. 2010. Т. 150. № 7. С. 80 - 84.
  6. Герштейн Е.С., Щербаков А.М., Платова А.М. и др. Экспрессия и активность ядерного транскрипционного фактора NF-kB, его ингибитора IкBa и протеинкиназы Akt1 в опухолях больных раком молочной железы // Альманах клинической медицины. 2010. Т. 22. С. 55 - 61.
  7. Кушлинский Н.Е., Герштейн Е.С., Овчинникова Л.К., Дигаева М.А. Биологические маркеры опухолей в клинике - достижения, проблемы, перспективы // Молекулярная медицина. 2008. № 3. С. 48 - 55.
  8. Щербаков А.М., Герштейн Е.С., Анурова О.А., Кушлинский Н.Е. Активированная протеинкиназа В при раке молочной железы // Бюллетень экспериментальной биологии и медицины. 2005. Т. 139. № 5. С. 570 - 572.
  9. Adli M., Baldwin A.S.IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation // J. Biol. Chem. 2006. V. 281. № 37. P. 26976 ? 26984.
  10. Ahmed K.M., Cao N., Li J.J.HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer // Anticancer Res. 2006. V. 26. № 6B. P. 4235 ? 4243.
  11. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB // J. Clin. Invest. 2001. V. 107. № 3. P. 241 - 246.
  12. Bhat-Nakshatri P., Sweeney C.J., Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells // Oncogene. 2002. V. 21. № 13. P. 2066 - 2078.
  13. Biswas D.K., Iglehart J.D.Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer // J. Cell Physiol. 2006. V. 209. № 3. P. 645 - 652.
  14. Cao Y., Karin M.NF-kappaB in mammary gland development and breast cancer // J. Mammary Gland Biol. Neoplasia. 2003. V. 8. № 2. P. 215 ? 223.
  15. Cardoso F., Ross J.S., Picart M.J. et al. Targeting the ubiquitin-proteasome pathway in breast cancer // Clin. Breast Cancer. 2004. V. 5. № 2. P. 148 ? 157.
  16. Chen F.Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control // Cancer Res. 2004. V. 64. № 22. P. 8135 ? 8138.
  17. Dan H.C., Cooper M.J., Cogswell P.C. et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK // Genes Dev. 2008. V. 22. № 11. P. 1490 - 1500.
  18. deGraffenried L.A., Chandrasekar B., Friedrichs W.E. et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen // Ann. Oncol. 2004. V. 15. № 6. P. 885 - 890.
  19. Gershtein E.S., Scherbakov A.M., Anurova O.A. et al. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels // Int. J. Biol. Markers. 2006. V. 21. № 1. P. 12 - 19.
  20. Gershtein E.S., Scherbakov A.M., Shatskaya V.A. et al. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations // Anticancer Res. 2007. V. 27. № 4A. P. 1777 - 1782.
  21. Gershtein E.S., Shatskaya V.A., Ermilova V.D. et al. Phospatidylinositol 3-kinase expression in human breast cancer // Clin. Chim. Acta. 1999. V. 287. № 1 - 2. P. 59 - 67.
  22. Hernandez-Vargas H., Rodriguez-Pinilla S.M., Julian-Tendero M. et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance // Breast Cancer Res. Treat. 2007. V. 102. № 2. P. 157 - 172.
  23. Jenkins C., Hewamana S., Gilkes A. et al. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia // Br. J. Haematol. 2008. V. 143. № 5. P. 661 ? 671.
  24. Jones M.D., Liu J.C., Barthel T.K. et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes // Clin. Cancer Res. 2010. V. 16. № 20. P. 4978 ? 4989.
  25. Kim H.J., Hawke N., Baldwin A.S.NF-kappaB and IKK as therapeutic targets in cancer // Cell Death Differ. 2006. V. 13. № 5. P. 738 - 747.
  26. Liu C., Zhou S., Ke C.S. et al.[Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression] // Ai Zheng.2007. V. 26. № 9. P. 929 - 936.
  27. Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB: ontrol of oncogenesis and cancer therapy resistance // Biochim. Biophys. Acta. 2000. V. 1470. № 2.  P. 55 - 62.
  28. Orlowski R.Z., Baldwin A.S., Jr. NF-kappaB as a therapeutic target in cancer // Trends Mol. Med. 2002. V.8. № 8. P. 385 - 389.
  29. Pajak B., Gajkowska B., Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells // Folia Histochem. Cytobiol. 2008. V. 46. № 2. P. 129 - 135.
  30. Park B.K., Zhang H., Zeng Q. et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF // Nat. Med. 2007. V. 13. № 1. P. 62 - 69.
  31. Pratt M.A., Bishop T.E., White D. et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence // Mol. Cell Biol. 2003. V.23. № 19. P. 6887 - 6900.
  32. Rahman K.M., Ali S., Aboukameel A. et al.Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells // Mol. Cancer Ther. 2007. V. 6. № 10. P. 2757 - 2765.
  33. Russo S.M., Tepper J.E., Baldwin A.S., Jr. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB // Int. J. Radiat. Oncol. Biol. Phys. 2001. V. 50. № 1. P. 183 - 193.
  34. Scherbakov A.M., Lobanova Y.S., Andreeva O.E. et al. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin // Biosci. Rep. 2010. V. 31. № 2. P. 137 - 143.
  35. Sliva D., Rizzo M.T., English D.Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator // J. Biol. Chem. 2002. V. 277. № 5. P. 3150 - 3157.
  36. Szoltysek K., Pietranek K., Kalinowska-Herok M. et al. TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-proficient cells // Acta Biochim. Pol. 2008. V. 55. № 4. P. 741 ? 748.
  37. Van Laere S.J., Van der Auwera I., Van den Eynden G.G. et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation // Br. J. Cancer. 2007. V. 97. № 5. P. 659 - 669.
  38. Weldon C.B., Burow M.E., Rolfe K.W. et al. NF-kappa B-mediated chemoresistance in breast cancer cells // Surgery. 2001. V. 130. № 2. P. 143 ? 150.
  39. Wu J.T., Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy // J. Surg. Res. 2005. V. 123. № 1. P. 158 ? 169.
  40. Xu J., Wu H.F., Ang E.S. et al.NF-kappaB modulators in osteolytic bone diseases // Cytokine Growth Factor Rev. 2009. V. 20. № 1. P. 7 - 17.
  41. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer // Endocr. Relat. Cancer. 2005. V. 12. Suppl. 1. P. 37 - 46.
  42. Zhou Y., Eppenberger-Castori S., Marx C. et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers // Int. J. Biochem. Cell Biol. 2005. V. 37. № 5. P. 1130 ? 1144.
  43. Zhou Y., Yau C., Gray J.W. et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer // BMC Cancer.2007. V. 7. P. 59.